Combined analysis of IGHV mutations, telomere length and CD49d identifies long-term progression-free survivors in TP53 wild-type CLL treated with FCR-based therapies

Pepper, Andrea; Zucchetto, Antonella; Norris, Kevin; Tissino, Erika; Polesel, Jerry; Soe, Zarni; Allsup, David; Hockaday, Anna; Ow, Pei Loo; Hillmen, Peter; Rawstron, Andrew; Catovsky, Daniel; Bulian, Pietro; Bomben, Riccardo; Baird, Duncan M; Fegan, Christopher D; Gattei, Valter; Pepper, Christopher

s41375-021-01322-1.pdf (716.63 kB)

Combined analysis of IGHV mutations, telomere length and CD49d identifies long-term progression-free survivors in TP53 wild-type CLL treated with FCR-based therapies

journal contribution

posted on 2023-06-10, 00:15 authored by Andrea PepperAndrea Pepper, Antonella Zucchetto, Kevin Norris, Erika Tissino, Jerry Polesel, Zarni Soe, David Allsup, Anna Hockaday, Pei Loo Ow, Peter Hillmen, Andrew Rawstron, Daniel Catovsky, Pietro Bulian, Riccardo Bomben, Duncan M Baird, Christopher D Fegan, Valter Gattei, Christopher PepperChristopher Pepper

No description supplied

Funding

Equipment Grant - Flow cytometer for cancer research; G2599; SUSSEX CANCER FUND FOR TREATMENT AND RESEARCH

ISSF pilot: In-vitro modelling and therapeutic targeting in lymphoid leukaemia; WELLCOME TRUST

History

Publication status

Published

File Version

Published version

Journal

Leukemia

ISSN

0887-6924

Publisher

Springer Nature

External DOI

https://doi.org/10.1038/s41375-021-01322-1

Volume

36

Page range

271-274

Event location

England

Department affiliated with

Clinical and Experimental Medicine Publications

Full text available

Yes

Peer reviewed?

Yes

Legacy Posted Date

2021-06-30

First Open Access (FOA) Date

2021-06-30

First Compliant Deposit (FCD) Date

2021-06-30

Combined analysis of IGHV mutations, telomere length and CD49d identifies long-term progression-free survivors in TP53 wild-type CLL treated with FCR-based therapies

Funding

Equipment Grant - Flow cytometer for cancer research; G2599; SUSSEX CANCER FUND FOR TREATMENT AND RESEARCH

ISSF pilot: In-vitro modelling and therapeutic targeting in lymphoid leukaemia; WELLCOME TRUST

History

Publication status

File Version

Journal

ISSN

Publisher

External DOI

Volume

Page range

Event location

Department affiliated with

Full text available

Peer reviewed?

Legacy Posted Date

First Open Access (FOA) Date

First Compliant Deposit (FCD) Date

Usage metrics

Categories

Keywords

Licence

Exports